Keyphrases
Bevacizumab
100%
Adrenoleukodystrophy
100%
Leukodystrophy
100%
Blood-brain Barrier Disruption
100%
Ruxolitinib
50%
Clinical Manifestations
50%
Endothelial Function
50%
Anisotropy
50%
Adrenal Insufficiency
50%
Late Gadolinium Enhancement
50%
Cortisol
50%
Endothelial Cell Line
50%
Enhanced Permeability
50%
Vascular Permeability
50%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
50%
VEGF Secretion
50%
Permeability Increase
50%
Immune Suppressants
50%
Medicine and Dentistry
Vasculotropin
100%
Blood Brain Barrier
100%
Leukodystrophy
100%
Corticotropin
60%
Adrenoleukodystrophy
40%
Bevacizumab
40%
Magnetic Resonance Imaging
20%
Endothelial Function
20%
Secretion (Process)
20%
Ruxolitinib
20%
Adrenal Insufficiency
20%
Hydrocortisone
20%
Endothelial Cell Line
20%
Immunosuppressive Drug
20%
Dexamethasone
20%
Gadolinium
20%
Neuroscience
Blood Brain Barrier
100%
Vascular Endothelial Growth Factor
100%
Leukodystrophy
100%
Adrenocorticotropic Hormone
60%
Bevacizumab
40%
Adrenoleukodystrophy
40%
Magnetic Resonance Imaging
20%
Dexamethasone
20%
Cortisol
20%
Ruxolitinib
20%
Cell Line
20%
Immunosuppressive Drug
20%
Adrenal Insufficiency
20%
Anisotropy
20%
Pharmacology, Toxicology and Pharmaceutical Science
Vasculotropin
100%
Leukodystrophy
100%
Blood-Brain Barrier
100%
Corticotropin
60%
Bevacizumab
40%
Adrenoleukodystrophy
40%
Gadolinium
20%
Immunosuppressive Agent
20%
Hydrocortisone
20%
Adrenal Insufficiency
20%
Dexamethasone
20%
Ruxolitinib
20%
Agricultural and Biological Sciences
Vascular Endothelial Growth Factor
100%
Blood-Brain Barrier
100%
Bevacizumab
40%
Adrenoleukodystrophy
40%
Endothelial Cells
20%
Cell Line
20%
Cortisol
20%
Magnetic Resonance Imaging
20%
Dexamethasone
20%